Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,841 |
Ending reported balance
After 2026-09-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 822 · Balance 37,297 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 2 · 2026-09-15 · Exercise / conversion · Acquired 1,019 · Balance 38,316 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 3 · 2026-09-15 · Exercise / conversion · Acquired 2,255 · Balance 40,571 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 4 · 2026-09-15 · Sale · Disposed 4,730 · Balance 35,841 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.52 · Expires 2029-11-20 | Direct | 6,574 |
Reported balance
After 2026-09-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-15 · Exercise / conversion · Disposed 822 · Balance 6,574 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2033-05-31 | Direct | 8,144 |
Reported balance
After 2026-09-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-15 · Exercise / conversion · Disposed 1,019 · Balance 8,144 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2034-06-14 | Direct | 18,032 |
Reported balance
After 2026-09-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-15 · Exercise / conversion · Disposed 2,255 · Balance 18,032 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
F2: The option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2021 Filed Feb 3, 2021 16:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 380 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-002078 · doc1.xml · derivative · entry 8 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,896 Underlying: Common Stock · 380 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 16:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 50 | $36.00 | $1,800.00 |
DisclosureSEC source: 0001567619-21-002078 · doc1.xml · nonDerivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,118 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 16:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 350 | $35.02 | $12,258.51 |
DisclosureSEC source: 0001567619-21-002078 · doc1.xml · nonDerivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,168 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $35.00 to $35.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 16:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,250 | $34.49 | $43,113.75 |
DisclosureSEC source: 0001567619-21-002078 · doc1.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,518 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $34.00 to $34.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 16:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 550 | $33.45 | $18,399.98 |
DisclosureSEC source: 0001567619-21-002078 · doc1.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,768 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $33.00 to $33.89, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 16:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,820 | $1.68 | $3,058.69 |
DisclosureSEC source: 0001567619-21-002078 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 16:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 380 | $1.68 | $638.63 |
DisclosureSEC source: 0001567619-21-002078 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 16:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,222 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-21-001012 · doc1.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,440 Underlying: Common Stock · 1,222 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. F3 · derivative.exercise_date: The option began vesting monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 16:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,222 | $0.58 | $709.00 |
DisclosureSEC source: 0001567619-21-001012 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 18:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,809 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-000468 · doc1.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,153 Underlying: Common Stock · 1,809 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 18:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 391 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-21-000468 · doc1.xml · derivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,276 Underlying: Common Stock · 391 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 18:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,200 | $27.82 | $61,214.56 |
DisclosureSEC source: 0001567619-21-000468 · doc1.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,896 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $27.50 to $28.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 18:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,809 | $1.68 | $3,040.21 |
DisclosureSEC source: 0001567619-21-000468 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 18:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 391 | $1.68 | $657.11 |
DisclosureSEC source: 0001567619-21-000468 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 20:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,222 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-20-021189 · doc1.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,662 Underlying: Common Stock · 1,222 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. F4 · derivative.exercise_date: The option began vesting monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 20:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,222 | $0.58 | $709.00 |
DisclosureSEC source: 0001567619-20-021189 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. F2 · balance_after: Includes 830 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2020. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,810 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-020620 · doc1.xml · derivative · entry 8 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,962 Underlying: Common Stock · 1,810 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 390 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-020620 · doc1.xml · derivative · entry 7 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,667 Underlying: Common Stock · 390 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 263 | $27.36 | $7,195.68 |
DisclosureSEC source: 0001567619-20-020620 · doc1.xml · nonDerivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,844 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $26.95 to $27.59, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,050 | $26.29 | $27,607.02 |
DisclosureSEC source: 0001567619-20-020620 · doc1.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,107 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $25.88 to $26.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 887 | $25.20 | $22,351.87 |
DisclosureSEC source: 0001567619-20-020620 · doc1.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,157 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $24.64 to $25.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,810 | $1.68 | $3,040.80 |
DisclosureSEC source: 0001567619-20-020620 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 00:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 390 | $1.68 | $655.20 |
DisclosureSEC source: 0001567619-20-020620 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 16:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,222 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-20-019438 · doc1.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,884 Underlying: Common Stock · 1,222 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. F3 · derivative.exercise_date: The option began vesting monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 16:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,222 | $0.58 | $709.00 |
DisclosureSEC source: 0001567619-20-019438 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:33 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,809 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-018692 · doc1.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,772 Underlying: Common Stock · 1,809 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:33 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 391 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-018692 · doc1.xml · derivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,057 Underlying: Common Stock · 391 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:33 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,200 | $18.27 | $40,186.08 |
DisclosureSEC source: 0001567619-20-018692 · doc1.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,622 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $18.02 to $18.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:33 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,809 | $1.68 | $3,039.12 |
DisclosureSEC source: 0001567619-20-018692 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:33 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 391 | $1.68 | $656.88 |
DisclosureSEC source: 0001567619-20-018692 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 18:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,222 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-20-017915 · doc1.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,106 Underlying: Common Stock · 1,222 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. F3 · derivative.exercise_date: The option began vesting monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 18:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,222 | $0.58 | $709.00 |
DisclosureSEC source: 0001567619-20-017915 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. Read SEC document |
| October 01, 2020 Filed Oct 6, 2020 01:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 390 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-017606 · doc1.xml · derivative · entry 7 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,448 Underlying: Common Stock · 390 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| October 01, 2020 Filed Oct 6, 2020 01:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,810 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-017606 · doc1.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,581 Underlying: Common Stock · 1,810 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| October 01, 2020 Filed Oct 6, 2020 01:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 390 | $25.18 | $9,820.71 |
DisclosureSEC source: 0001567619-20-017606 · doc1.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,400 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $27.68 to $28.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 01, 2020 Filed Oct 6, 2020 01:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 390 | $1.68 | $655.20 |
DisclosureSEC source: 0001567619-20-017606 · doc1.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 01, 2020 Filed Oct 6, 2020 01:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,810 | $28.18 | $51,008.15 |
DisclosureSEC source: 0001567619-20-017606 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,400 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $27.68 to $28.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 01, 2020 Filed Oct 6, 2020 01:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,810 | $1.68 | $3,040.80 |
DisclosureSEC source: 0001567619-20-017606 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,222 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-20-016809 · doc1.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,328 Underlying: Common Stock · 1,222 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. F3 · derivative.exercise_date: The option began vesting monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:57 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,222 | $0.58 | $709.00 |
DisclosureSEC source: 0001567619-20-016809 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 15:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,200 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-016301 · doc1.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,810 Underlying: Common Stock · 2,200 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 15:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,200 | $24.38 | $53,643.26 |
DisclosureSEC source: 0001567619-20-016301 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,178 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $24.00 to $25.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 15:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,200 | $1.68 | $3,696.00 |
DisclosureSEC source: 0001567619-20-016301 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 01, 2020 Filed Oct 6, 2020 01:12 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,172 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-017605 · doc1.xml · derivative · entry 7 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,838 Underlying: Common Stock · 1,172 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| September 01, 2020 Filed Oct 6, 2020 01:12 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,028 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-017605 · doc1.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,391 Underlying: Common Stock · 1,028 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| September 01, 2020 Filed Oct 6, 2020 01:12 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,172 | $24.38 | $28,577.23 |
DisclosureSEC source: 0001567619-20-017605 · doc1.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,178 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $24.00 to $25.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Oct 6, 2020 01:12 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,172 | $1.68 | $1,968.96 |
DisclosureSEC source: 0001567619-20-017605 · doc1.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 01, 2020 Filed Oct 6, 2020 01:12 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,028 | $24.38 | $25,066.03 |
DisclosureSEC source: 0001567619-20-017605 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,178 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $24.00 to $25.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Oct 6, 2020 01:12 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,028 | $1.68 | $1,727.04 |
DisclosureSEC source: 0001567619-20-017605 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 18:19 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-015854 · doc1.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,982 Underlying: Common Stock · 5,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. F3 · derivative.exercise_date: The option began vesting on March 13, 2019 and will vest monthly over a four year period, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.